---
title: "Turn Therapeutics sells 135,000 shares in private placement for $1.35 million"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296141997.md"
description: "Turn Therapeutics completed a private placement of 135,000 common shares to existing series and seed investors at $10 per share, raising $1.35 million in gross proceeds. The unregistered offering occurred under Section 4(a)(2) and Regulation D on August 14, 2026, with investors granted registration rights."
datetime: "2026-08-17T20:16:53.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296141997.md)
  - [en](https://longbridge.com/en/news/296141997.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296141997.md)
generator: "portal-rs"
---

# Turn Therapeutics sells 135,000 shares in private placement for $1.35 million

-   Turn Therapeutics entered securities purchase agreements on Aug. 14, 2026 for a private placement of common stock. \* Accredited investors agreed to buy 135,000 shares at USD 10 per share for USD 1.35 million in gross proceeds. \* Buyers were existing series and seed investors. \* Shares were sold in an unregistered offering under Section 4(a)(2) and Regulation D. \* Investors received registration rights covering the shares. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Turn Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-090766), on August 17, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [TTRX.US](https://longbridge.com/en/quote/TTRX.US.md)

## Related News & Research

- [Turn Therapeutics says mouse study shows GX-03 cuts dermatitis severity 66%](https://longbridge.com/en/news/296487429.md)
- [Rapport Therapeutics Chief Development Officer Krishnaswamy Yeleswaram disposes of 404 common shares worth $20,159.6](https://longbridge.com/en/news/296531261.md)
- [Palvella Therapeutics COO Kathleen Goin reports sale of 4,302 common shares worth $654,184.41](https://longbridge.com/en/news/296530942.md)
- [Corteva plans split into two publicly traded crop protection and seed companies by Oct. 1, 2026](https://longbridge.com/en/news/296487831.md)
- [Almi Invest GreenTech joins EUR 4 million seed round in Solinide Photonics](https://longbridge.com/en/news/296451878.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**